Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$7.2MCash on Hand
6.1mo Cash Runway
Follow SDEV by emailGet an email when SDEV reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about SDEV, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Shareholder vote Stockholders elected Michael Kazley, Yenyou (Jeff) Zheng and Russell Preston Cann as Class I directors at the November 10, 2026 annual meeting, and ratified CBIZ CPAs P.C. as independent auditor for fiscal 2026. Quorum was 91.4% of shares outstanding. Form 8-K · SEC filing
Oct 29, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 29, 2026 ·
Earnings Reported Q3 2026 results: net income of $50.4 million, or $0.23 per share, driven by a $58.8 million non-cash unrealized gain as SKY price rose about 49%. Staking revenue was $2.1 million for the quarter. Holds 2,321,079,862 SKY tokens, about 10% of supply. Form 8-K · SEC filing · Press release
Oct 5, 2026 ·
Earnings Held 2,321,079,862 SKY tokens as of September 30, 2026, with fair value of about $180.2 million, up from $119.2 million at June 30, 2026. Earned about 34.6 million SKY in staking rewards in the quarter and held about $7.2 million in cash with no debt. Form 8-K · SEC filing · Press release
Sep 29, 2026 ·
Listing Stablecoin Development Corp said it became aware of unusual trading in its common stock on the NYSE American on September 29, 2026. It stated it has made inquiries, is not aware of material non-public information or pending transactions that could explain the activity, and has no undisclosed material developments. Form 8-K · SEC filing
Sep 28, 2026 ·
Shareholder vote Stablecoin Development Corp will hold its annual meeting on November 10, 2026, where stockholders vote to elect three Class I directors (Michael Kazley, Yenyou (Jeff) Zheng and Russell Preston Cann) and to ratify CBIZ CPAs P.C. as independent auditor for fiscal 2026. The board recommends voting FOR both proposals. Form DEF 14A · SEC filing
Sep 8, 2026 ·
Leadership Appointed David Garcia Rios as a Class II director, effective immediately, as the nominee of shareholder Sky Frontier Foundation under the January 2026 Investors' Rights Agreement. Director pay is $40,000 in cash annually. Eliminated preferred stock series remain at zero outstanding. Form 8-K · SEC filing
Aug 11, 2026 ·
Financing Registers for resale up to 212,876,259 common shares held by selling stockholders, including 167,539,227 shares issuable on January 2026 pre-funded warrants at $0.05 per share. The company receives no offering proceeds except warrant exercise cash. Last reported price was $1.02 on August 10, 2026. Form S-3 · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
SDEV holds $7.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $3.5M/quarter from operations,
an estimated runway of 6.1 months at that rate (BioRadar estimate, not company guidance).
Share count 73,117,016 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full SDEV picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SDEV and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.